Wentworth CE - Search Results

1

The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus.

Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG. Burke TA, et al. Among authors: wentworth ce. Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):979-87. doi: 10.1002/pds.1444. Pharmacoepidemiol Drug Saf. 2007. PMID: 17605137

2

Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice.

Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Burke TA, et al. Among authors: wentworth ce. J Hypertens. 2006 Jun;24(6):1193-200. doi: 10.1097/01.hjh.0000226211.95936.f5. J Hypertens. 2006. PMID: 16685222

3

Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.

Zhao SZ, Wentworth C, Burke TA, Makuch RW. Zhao SZ, et al. Pharmacoepidemiol Drug Saf. 2004 May;13(5):277-87. doi: 10.1002/pds.909. Pharmacoepidemiol Drug Saf. 2004. PMID: 15133778

4

Lipid testing among patients beginning statin therapy in general practice in the United Kingdom.

Phatak H, Wentworth C, Burke TA. Phatak H, et al. Value Health. 2008 Sep-Oct;11(5):933-8. doi: 10.1111/j.1524-4733.2008.00345.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489501 Free article.

5

Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice.

Phatak H, Wentworth C, Sazonov V, Burke T. Phatak H, et al. Atherosclerosis. 2009 Jan;202(1):225-33. doi: 10.1016/j.atherosclerosis.2008.03.016. Epub 2008 Mar 27. Atherosclerosis. 2009. PMID: 18457840

6

Dosage, titration, and gaps in treatment with extended release niacin in clinical practice.

Kamal-Bahl SJ, Burke TA, Watson DJ, Wentworth CE. Kamal-Bahl SJ, et al. Among authors: wentworth ce. Curr Med Res Opin. 2008 Jun;24(6):1817-21. doi: 10.1185/03007990802083408. Epub 2008 May 15. Curr Med Res Opin. 2008. PMID: 18485268

7

Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice.

Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Kamal-Bahl SJ, et al. Am J Cardiol. 2007 Feb 15;99(4):530-4. doi: 10.1016/j.amjcard.2006.08.063. Epub 2006 Dec 28. Am J Cardiol. 2007. PMID: 17293198

8

Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice.

Chandwani S, Wentworth C, Burke TA, Patterson TF. Chandwani S, et al. Curr Med Res Opin. 2009 Feb;25(2):385-93. doi: 10.1185/03007990802619599. Curr Med Res Opin. 2009. PMID: 19192983

9

Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.

Osterhaus JT, Burke TA, May C, Wentworth C, Whelton A, Bristol S. Osterhaus JT, et al. Clin Ther. 2002 Jun;24(6):969-89. doi: 10.1016/s0149-2918(02)80011-x. Clin Ther. 2002. PMID: 12117086

10

Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.

Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ. Arellano FM, et al. Among authors: wentworth ce. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):861-72. doi: 10.1002/pds.1343. Pharmacoepidemiol Drug Saf. 2006. PMID: 17086563

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters